Search Results for "Generess Fe Vs Yaz"

14:16 EDT 1st October 2014 | BioPortfolio

Matching Channels

None

Matching News

Actavis Agrees to Generess FE Patent Settlement

Actavis plc announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd.Read more

Actavis announces agreement related to Generess FE patent challenge litigation

Actavis has announced that it has entered into an agreement with Mylan and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethin...

Actavis: Agreement Over Generess FE Patent Challenge Litigation

WASHINGTON (dpa-AFX) - Actavis plc (ACT) said Tuesday it has entered into an agreement with Mylan Inc (MYL) and Famy Care Ltd to settle all outstanding patent litigation related to Mylan's generic...

Mylan settles over generic Generess tablets and launches insomnia drug

US generics major Mylan (Nasdaq: MYL) and its partner Famy Care have entered into a settlement and license agreement settling litigation over Mylan’s filing of an Abbreviated New Drug Application (A...

Actavis Announces Agreement Related to Generess® FE Patent Challenge Litigation

DUBLIN, April 15, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation rela...

Mylan Announces Settlement Agreement for First-to-File Generess® Fe

PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it and its partner Famy Care Ltd. have entered into a settlement and license agreement with Warner Chilcott Com...

Actavis Announces Departure of G. Frederick Wilkinson, President, Actavis Global R&D

DUBLIN, April 21, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that G. Frederick Wilkinson, President, Actavis Global R&D, will leave the Company effective April 25, 2014....

Actavis Net Revenue Increases 40% to $2.66 Billion in First Quarter 2014; Non-GAAP EPS Increases 75% to $3.49

DUBLIN, April 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billi...

Matching PubMed Articles

None

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement